

## NOTE

# MBJ-0110, a novel cyclopeptide isolated from the fungus *Penicillium* sp. f25267

Teppei Kawahara<sup>1</sup>, Masashi Itoh<sup>2</sup>, Ikuko Kozono<sup>1</sup>, Miho Izumikawa<sup>1</sup>, Noriaki Sakata<sup>2</sup>, Toshio Tsuchida<sup>2</sup> and Kazuo Shin-ya<sup>3</sup>

*The Journal of Antibiotics* advance online publication, 8 July 2015; doi:10.1038/ja.2015.78

We have constructed an isolated natural compound library designed to facilitate extensive biological screenings.<sup>1</sup> The library consists of over 1000 isolates, including over 140 'JBIR compounds' that were discovered in our laboratory. To enrich this library, we recently initiated a screening program for rare microbial products using the advanced compound-identification system designated as 'MBJ's special selection'.<sup>2,3</sup> As a result, our program yielded novel compounds named 'MBJ compounds', such as a cytotoxic hydroxamate MBJ-0003 from *Micromonospora* sp. 29867;<sup>4</sup> cytotoxic eremophilane derivatives MBJ-0009 and MBJ-0010 from *Nectria* sp. f26111;<sup>5</sup> MBJ-0011, MBJ-0012 and MBJ-0013 from *Apiognomonina* sp. f24023;<sup>2</sup> cytotoxic chaetoglobosin derivatives MBJ-0038, MBJ-0039 and MBJ-0040 from *Chaetomium* sp. f24230;<sup>3</sup> bicyclic depsipeptides MBJ-0086 and MBJ-0087 from *Sphaerisporangium* sp. 33226;<sup>6</sup> and aziridine-containing peptide MBJ-0035 from *Streptosporangium* sp. 32552.<sup>7</sup> Further screening for novel compounds led to the identification of MBJ-0110 (**1**) from the culture of *Penicillium* sp. f25267. Herein we report the fermentation, isolation, structure elucidation and preliminary biological activity data.

*Penicillium* sp. f25267 was isolated from a soil sample collected in the Shiga Prefecture, Japan. The strain was cultured in 250-ml Erlenmeyer flasks, each containing 25 ml of a seed medium consisting of 2% potato starch (Tobu Tokachi Nosan Kako Agricultural Cooperative Assoc., Hokkaido, Japan), 1% glucose (Junsei Chemical, Tokyo, Japan), 2% soybean powder (SoyPro, J-Oil Mills, Tokyo, Japan), 0.1% KH<sub>2</sub>PO<sub>4</sub> and 0.05% MgSO<sub>4</sub>·7H<sub>2</sub>O (pH 7.4 before sterilization). The flasks were incubated on a rotary shaker (220 r.p.m.) at 25 °C for 3 days. Aliquots (0.5 ml) of the broth were transferred to 500-ml Erlenmeyer flasks containing 50 ml of a production medium of the same composition, which were then cultured on a rotary shaker (220 r.p.m.) at 25 °C for 4 days.

The whole culture broth (2 l) was extracted with an equal volume of *n*-BuOH. After concentration *in vacuo*, the extract was successively partitioned between EtOAc (350 ml×3) and H<sub>2</sub>O (300 ml). The aqueous layer was evaporated to dryness and the residue (1.4 g) was fractionated by reversed-phase medium-pressure liquid chromatography

(Purif-Pack ODS-30, Shoko Scientific, Yokohama, Japan; 40–100% aq. MeOH with 10% stepwise increments in the MeOH concentration). The fractions were monitored using an ultra performance liquid chromatography-diode array detection-evaporative light scattering-mass spectrometry system and **1** was isolated based on peak-guided fractionation. The 50% MeOH eluate (30.9 mg) was subjected to preparative reversed-phase HPLC using a Capcell Pak C<sub>18</sub> MG II column (20 mm inside diameter (i.d.)×150 mm; Shiseido, Tokyo, Japan) with a solvent system of 20% CH<sub>3</sub>CN/H<sub>2</sub>O containing 0.1% formic acid (flow rate: 10 ml min<sup>-1</sup>), to yield semi-purified **1** (6.9 mg, retention time (Rt)=15.3 min). Final purification was carried out by preparative HPLC using an X-Bridge C<sub>18</sub> column (19 mm i.d.×150-mm; Waters, Milford, MA, USA) with a solvent system of 20% CH<sub>3</sub>CN/H<sub>2</sub>O containing 0.1% formic acid (flow rate: 10 ml min<sup>-1</sup>) to afford **1** (3.5 mg, Rt=13.3 min).

MBJ-0110 (**1**) was obtained as a colorless amorphous powder: [α]<sub>D</sub><sup>24</sup> –186 (MeOH; *c* 0.18); UV end; IR (attenuated total reflectance) ν<sub>max</sub>: 3400 (hydroxy) and 1683 (carbonyl) cm<sup>-1</sup>. The molecular formula of **1** was established as C<sub>27</sub>H<sub>41</sub>N<sub>5</sub>O<sub>8</sub> by high-resolution (HR)-ESI-MS (*m/z* 564.3018 [M+H]<sup>+</sup>, calcd for C<sub>27</sub>H<sub>42</sub>N<sub>5</sub>O<sub>8</sub> *m/z* 564.3033). Its peptidic nature was evident from the resonances corresponding to α-methine protons (δ<sub>H</sub> 4.00–5.08) and the resonances corresponding to the carbonyl carbons (δ<sub>C</sub> 169.0–175.9) in the <sup>1</sup>H and <sup>13</sup>C NMR spectra of **1**, respectively. The direct connectivity between protons and carbons was established by a HSQC spectrum; Table 1 summarizes the <sup>13</sup>C and <sup>1</sup>H NMR spectroscopic data for **1**. The <sup>1</sup>H sequences and <sup>1</sup>H–<sup>13</sup>C long-range couplings from α-methine protons to the corresponding amide carbonyl carbons, which were elucidated by double quantum-filtered COSY and constant time-HMBC<sup>8</sup> spectra, respectively, revealed the involvement of an isoleucine (Ile), a pipecolic acid (Pip), a proline (Pro) and an aspartic acid (Asp) residue, as shown in Figure 1b. In addition to the above-mentioned amino-acid moieties, the presence of a 4-hydroxypipecolic acid (C-22 to C-27) moiety was proved based on a <sup>1</sup>H sequence from an α-methine proton H-23 (δ<sub>H</sub> 4.00) to nitrogen-bearing methylene protons H<sub>2</sub>-27 (δ<sub>H</sub> 3.39 and 2.98) via aliphatic methylene protons

<sup>1</sup>Japan Biological Informatics Consortium (JBIC), Koto-ku, Tokyo, Japan; <sup>2</sup>Bioresource Laboratories, MicroBiopharm Japan Co., Ltd. (MBJ), Iwata, Shizuoka, Japan and <sup>3</sup>National Institute of Advanced Industrial Science and Technology (AIST), Koto-ku, Tokyo, Japan  
Correspondence: Dr K Shin-ya, National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan.  
E-mail: k-shinya@aist.go.jp

Received 7 April 2015; revised 8 June 2015; accepted 15 June 2015

**Table 1**  $^{13}\text{C}$  and  $^1\text{H}$  NMR spectroscopic data for **1**

Position	$\delta_{\text{C}}$	$\delta_{\text{H}}$ , multiplicity (J in Hz)
1	169.7	
2	59.2	4.36, d (7.8)
3	39.7	1.68, ovl <sup>a</sup>
4	26.7	1.52, m; 1.19, m
5	11.4	0.95, t (7.2)
6	15.9	0.93, d (6.6)
7	173.0	
8	54.8	5.08, br s
9	25.0	2.20, ovl <sup>a</sup> ; 1.62, ovl <sup>a</sup>
10	20.9	1.78, ovl <sup>a</sup> ; 1.70, ovl <sup>a</sup>
11	25.5	1.73, ovl <sup>a</sup> ; 1.73, ovl <sup>a</sup>
12	45.0	3.97, br d (15.6); 3.00, ovl <sup>a</sup>
13	175.9	
14	59.7	4.95, dd (4.8, 8.4)
15	30.0	2.47, m; 1.80, ovl <sup>a</sup>
16	26.3	2.08, ovl <sup>a</sup> ; 1.96, ovl <sup>a</sup>
17	50.2	3.76, ovl <sup>a</sup> ; 3.70, ovl <sup>a</sup>
18	171.3	
19	37.0	3.10, dd (7.2, 12.0); 2.96, ovl <sup>a</sup>
20	51.7	4.82, m
21	175.7	
22	169.0	
23	55.5	4.00, d (7.2)
24	32.8	2.62, br d (13.8); 2.07, ovl <sup>a</sup>
25	68.9	5.17, br s
26	26.8	2.19, ovl <sup>a</sup> ; 2.02, ovl <sup>a</sup>
27	40.6	3.39, br d (9.6); 2.98, ovl <sup>a</sup>


<sup>a</sup>Overlapped with other signals. NMR spectra were taken on a 600 NB CL NMR system (Varian, Palo Alto, CA, USA) in  $\text{CD}_3\text{OD}$  with the residual solvent peak as an internal standard ( $\delta_{\text{C}}$  49.0,  $\delta_{\text{H}}$  3.31 p.p.m.).

$\text{H}_2\text{-24}$  ( $\delta_{\text{H}}$  2.62 and 2.07), an oxymethine proton  $\text{H-25}$  ( $\delta_{\text{H}}$  5.17,  $\delta_{\text{C}}$  68.9) and aliphatic protons  $\text{H}_2\text{-26}$  ( $\delta_{\text{H}}$  2.19, 2.02), and  $^1\text{H-}^{13}\text{C}$  long-range couplings from  $\text{H-23}$  and  $\text{H-24}$  ( $\delta_{\text{H}}$  2.07) to an amide carbonyl carbon  $\text{C-22}$  ( $\delta_{\text{C}}$  169.0), and from  $\text{H}_2\text{-27}$  to an  $\alpha$ -methine carbon  $\text{C-23}$  ( $\delta_{\text{C}}$  55.5).

The amino-acid sequence in **1** was determined by the HMBC correlations from an  $\alpha$ -methine proton  $\text{H-2}$  ( $\delta_{\text{H}}$  4.36) to a carbonyl carbon  $\text{C-7}$  ( $\delta_{\text{C}}$  173.0), from an  $\alpha$ -methine proton  $\text{H-8}$  ( $\delta_{\text{H}}$  5.08) and  $\epsilon$ -methylene protons  $\text{H}_2\text{-12}$  ( $\delta_{\text{H}}$  3.97 and 3.00) to a carbonyl carbon  $\text{C-13}$  ( $\delta_{\text{C}}$  175.9), from an  $\alpha$ -methine proton  $\text{H-14}$  ( $\delta_{\text{H}}$  4.95) to a carbonyl carbon  $\text{C-18}$  ( $\delta_{\text{C}}$  171.3), from an  $\alpha$ -methine proton  $\text{H-20}$  ( $\delta_{\text{H}}$  4.82) to  $\text{C-22}$  and from  $\text{H-25}$  to an ester carbonyl carbon  $\text{C-1}$  ( $\delta_{\text{C}}$  169.7). Although only  $^1\text{H-}^{13}\text{C}$  HMBC information suggested two structural possibilities,  $\alpha$ - and  $\beta$ -aspartyl amide linkages, we concluded that the aspartyl acid moiety is linked to adjacent Pro by  $\beta$ -amino bond because of the existence of a ROESY correlation between  $\text{H}_b\text{-17}$  ( $\delta_{\text{H}}$  3.70) and  $\text{H}_a\text{-19}$  ( $\delta_{\text{H}}$  3.10) and  $^1\text{H-}^{15}\text{N}$  HMBC correlations from  $\text{H}_2\text{-16}$  ( $\delta_{\text{H}}$  2.08, 1.96),  $\text{H}_b\text{-15}$  ( $\delta_{\text{H}}$  1.80) and  $\text{H}_b\text{-19}$  ( $\delta_{\text{H}}$  2.96) to a nitrogen atom of Pro ( $\delta_{\text{N}}$  140). Therefore, the structure of **1** was determined as shown in Figure 1b.

To verify the proposed structure, **1** was treated with 0.1 N NaOH overnight at room temperature, followed by ESI-MS/MS analysis of the alkaline hydrolysate (molecular formula:  $\text{C}_{27}\text{H}_{43}\text{N}_5\text{O}_9$ ; HR-ESI-MS:  $[\text{M}+\text{H}]^+$   $m/z$  582.3159,  $\text{C}_{27}\text{H}_{44}\text{N}_5\text{O}_9$  582.3139). The ESI-MS/MS data showed major fragment ions ( $m/z$  185.0945, 243.0976, 324.1554, 340.1477 and 451.2165) that supported the proposed structure (Figure 1c).

The multiplicity and a large  $^1\text{H}$  spin coupling constant value of  $\text{H-23}$  (doublet,  $J_{\text{H-H}}=7.2$  Hz) and ROESY correlations between  $\text{H-23}/\text{H}_{\text{ax}}\text{-27}$  ( $\delta_{\text{H}}$  2.98) and  $\text{H-23}/\text{H}_{\text{eq}}\text{-24}$  ( $\delta_{\text{H}}$  2.62) implied that the piperidine ring is in the chair conformation and the  $\text{H-23}$  is axially orientated. In addition, the broad singlet signal of  $\text{H-25}$  proved its



**Figure 1** (a) Structure of **1**. (b) NMR analysis of **1**. COSY, bold line;  $^1\text{H-}^{13}\text{C}$  HMBC, solid arrow;  $^1\text{H-}^{15}\text{N}$  HMBC, dashed arrow; ROESY, bidirectional dashed arrow. (c) ESI-MS/MS fragmentation ions of **1**.

equatorial orientation. Taken together, the relative configurations of C-23 and C-25 were determined as 23S\* and 25S\*, respectively.

The absolute configurations of the amino-acid residues were determined to be L-Pro, L-Pip and L-Asp by using Marfey's method.<sup>9</sup> A portion of **1** (0.4 mg) was hydrolyzed in 6 N HCl at 110 °C for 12 h and then dried under air flow. The resulting hydrolysate was treated with 0.1 M NaHCO<sub>3</sub> (200 µl) and 1% N-(5-fluoro-2,4-dinitrophenyl)-L-alaninamide (L-FDAA) in Me<sub>2</sub>CO (100 µl) at 40 °C for 30 min. Amino-acid standards were derivatized with L-FDAA in a similar manner. The Marfey's derivatives were analyzed using a HPLC–MS system as follows: a Capcell Pak C<sub>18</sub> MG II column (4.6 mm i.d.×150 mm) was developed with a linear gradient system of water/MeCN with 0.1% formic acid (20–50% MeCN, 15 min; flow rate, 1.0 ml min<sup>−1</sup>). FDAA derivatives were detected by absorption at 340 nm, and assignment was secured by ion-selective monitoring. The retention times of the standard FDAA derivatives were as follows: L-Asp, 7.9 min; D-Asp, 8.2 min; L-Pip, 13.6 min; D-Pip, 12.8 min; L-Pro, 10.1 min; D-Pro, 10.7 min; L-Ile, 14.7 min; D-Ile, 16.8 min; L-*allo*-Ile, 14.7 min; and D-*allo*-Ile, 16.7 min. The retention times of the FDAA derivatives of **1** were as follows: Asp, 7.9 min; Pip, 13.6 min; Pro, 10.1 min; and Ile, 14.7 min.

The absolute configuration of the Ile residue in **1** was established by HPLC comparison of the 2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranosyl isothiocyanate (GITC) derivative of hydrolysate of **1** with standard samples.<sup>10</sup> Triethylamine (50 µl) and a GITC solution (250 µl, prepared at 3.9 mg ml<sup>−1</sup> in CH<sub>3</sub>CN) were added to the acid hydrolysate of **1** or an authentic amino-acid standard. The reaction mixture was kept at room temperature for 30 min and the reaction was then quenched by adding 40 µl of MeCN–5% AcOH in H<sub>2</sub>O (1:1). Analysis of the GITC derivatives was performed on a Capcell Pak ADME column (4.6 mm i.d.×150 mm; Shiseido) employing an isocratic elution of 40% CH<sub>3</sub>CN containing 0.1% formic acid (1.0 ml min<sup>−1</sup>). GITC derivatives were detected by absorption at 248 nm, and assigned by ion-selective monitoring. The retention times of the GITC derivatives were as follows: L-Ile, 11.6 min and L-*allo*-Ile, 11.3 min. The retention time (11.6 min) of the GITC derivative of **1** implied that the Ile residue in **1** is L-Ile.

We evaluated the cytotoxic and antimicrobial activities of **1**, but it showed neither cytotoxicity to human ovarian adenocarcinoma SKOV-3 cell lines (IC<sub>50</sub>>100 µM) or human malignant pleural

mesothelioma ACC-MESO-1 cell lines (IC<sub>50</sub>>100 µM), nor antimicrobial activity against *Micrococcus luteus* and *Bacillus subtilis*.

The obtained structure of **1** is very rare in nature; only petrosifungins A and B,<sup>11</sup> and JBIR-113, -114 and -115<sup>12</sup> have been isolated as pipecolic acid-containing peptides of fungal origin. To the best of our knowledge, there are no reports in the literature of peptide compounds possessing the 4-hydroxypipicolic acid moiety.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGEMENTS

This work was supported in part by a grant 'Project focused on developing key technologies for discovering and manufacturing drugs for next-generation treatment and diagnosis' from the Ministry of Economy, Trade and Industry (METI).

- 1 Kawahara, T., Nagai, A., Takagi, M. & Shin-ya, K. JBIR-137 and JBIR-138, new secondary metabolites from *Aspergillus* sp. fA75. *J. Antibiot.* **65**, 535–538 (2012).
- 2 Kawahara, T. et al. Three eremophilane derivatives, MBJ-0011, MBJ-0012 and MBJ-0013, from an endophytic fungus *Apiognomonina* sp. f24023. *J. Antibiot.* **66**, 299–302 (2013).
- 3 Kawahara, T. et al. New chaetoglobosin derivatives, MBJ-0038, MBJ-0039 and MBJ-0040, isolated from the fungus *Chaetomium* sp. f24230. *J. Antibiot.* **66**, 727–730 (2013).
- 4 Kawahara, T. et al. New hydroxamate metabolite, MBJ-0003, from *Micromonospora* sp. 29867. *J. Antibiot.* **67**, 261–263 (2014).
- 5 Kawahara, T. et al. Cytotoxic sesquiterpenoids MBJ-0009 and MBJ-0010 from a saprobic fungus *Nectria* sp. f26111. *J. Antibiot.* **66**, 567–569 (2013).
- 6 Kawahara, T. et al. MBJ-0086 and MBJ-0087, new bicyclic depsipeptides from *Sphaerisporangium* sp. 33226. *J. Antibiot.* **68**, 67–70 (2015).
- 7 Kawahara, T. et al. MBJ-0034 and MBJ-0035, new aziridine-containing peptides from *Streptosporangium* sp. 32552. *J. Antibiot.* **67**, 577–580 (2014).
- 8 Furihata, K. & Seto, H. Constant time HMBC (CT-HMBC), a new HMBC technique useful for improving separation of cross peaks. *Tetrahedron Lett.* **39**, 7337–7340 (1998).
- 9 Marfey, P. Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-2,4-dinitrobenzene. *Carlsberg Res. Commun.* **49**, 591–596 (1984).
- 10 Nimura, N., Ogura, H. & Kinoshita, T. Reversed-phase liquid chromatographic resolution of amino acid enantiomers by derivatization with 2,3,4,5-tetra-*O*-acetyl-β-D-glucopyranosyl isothiocyanate. *J. Chromatogr.* **202**, 375–379 (1980).
- 11 Bringmann, G., Lang, G., Steffens, S. & Schaumann, K. Petrosifungins A and B, novel cyclodepsipeptides from a sponge-derived strain of *Penicillium brevicompactum*. *J. Nat. Prod.* **67**, 311–315 (2004).
- 12 Kawahara, T., Takagi, M. & Shin-ya, K. Three new depsipeptides, JBIR-113, JBIR-114 and JBIR-115, isolated from a marine sponge-derived *Penicillium* sp. fS36. *J. Antibiot.* **65**, 147–150 (2012).